Objective To explore the efficacy and safety of desloratadine citrate disodium combined with pimecrolimus in the treatment of facial recurrent dermatitis. Methods A total of 68 patients with facial recurrent dermatitis admitted to the outpatient department of Wujin District Center for Disease Control and Prevention from March to December 2024 were selected as the research subjects, and they were divided into the control group and the treatment group by the random number table method, with 34 patients in each group. The control group was treated with desloratadine citrate disodium+vitamin E cream, and the treatment group was treated with desloratadine citrate disodium combined with pimecrolimus. The clinical related indicators, clinical efficacy, recurrence rate, adverse reactions and quality of life were compared between the two groups. Results The disappearance time of pruritus and pain in the treatment group was shorter than that in the control group (P <0.05). The total effective rate of treatment in the treatment group (97.06%) was higher than that in the control group (64.71%) (P <0.05). The recurrence rate and incidence of adverse reactions in the treatment group were lower than those in the control group, and the scores of all dimensions of quality of life were higher than those in the control group (P <0.05). Conclusion The regimen of desloratadine citrate disodium combined with pimecrolimus has a definite effect in the treatment of facial recurrent dermatitis. It can effectively control the progression of the disease, relieve symptoms, optimize quality of life, and reduce the risk of adverse reactions and disease recurrence.